Arsenic trioxide (Trisenox)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:27, 13 May 2012 by Dryang (talk | contribs) (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

General information

Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro.[1][2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Arsenic trioxide (Trisenox) package insert
  2. ↑ Arsenic trioxide (Trisenox) package insert (locally hosted backup)
  3. ↑ Arsenic trioxide (Trisenox) patient drug information (Chemocare)
  4. ↑ Arsenic trioxide (Trisenox) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Arsenic_trioxide_(Trisenox)&oldid=1347"